Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | POLR1A | O95602 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214022 | 1.00 | ACKR3 (0.40) | ACKR3CYP1A2ALDH1A1SIGMAR1FPR3 | |
| SCHEMBL7514193 | 0.86 | ACKR3 (0.35) | ACKR3CYP1A2ALDH1A1SIGMAR1FPR3 | |
| SCHEMBL7514191 | 0.86 | ACKR3 (0.35) | ACKR3CYP1A2ALDH1A1SIGMAR1FPR3 | |
| SCHEMBL7213907 | 0.81 | CA12 (0.40) | CYP1A2ALDH1A1SIGMAR1HRH3 | |
| SCHEMBL7220238 | 0.81 | CA12 (0.40) | CYP1A2ALDH1A1SIGMAR1HRH3 | |
| SCHEMBL27457772 | 0.81 | CA12 (0.40) | CYP1A2ALDH1A1SIGMAR1HRH3 | |
| SCHEMBL7213998 | 0.80 | SIGMAR1 (0.46) | ALDH1A1SIGMAR1 | |
| SCHEMBL6731438 | 0.79 | PKM (0.41) | ALDH1A1SIGMAR1EPHX1 | |
| SCHEMBL7220859 | 0.79 | SIGMAR1 (0.36) | SIGMAR1EPHX1HRH3 | |
| SCHEMBL7220863 | 0.79 | SIGMAR1 (0.36) | SIGMAR1EPHX1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1148349-C | N-substituted-N' -substituted urea derivatives and their use as TNF-alpha production inhibitors | ������ҩ��ʽ���� | 2004-05-05 | — | — | CN | disclosed |
| US-6534499-B2 | For therapy of autoimmune disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | US | disclosed |
| CN-1352632-A | N-substituted-N' -substituted urea derivatives and their use as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2002-06-05 | — | — | CN | disclosed |
| EP-1172359-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | TNF, NFKBIA, CHUK | ACKR3 1677/4885CYP1A2 1613/4885ALDH1A1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.